SCI Pharmtech Past Earnings Performance
Past criteria checks 0/6
SCI Pharmtech's earnings have been declining at an average annual rate of -20.9%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 21.2% per year. SCI Pharmtech's return on equity is 5.8%, and it has net margins of 24.5%.
Key information
-20.9%
Earnings growth rate
-21.0%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | -21.2% |
Return on equity | 5.8% |
Net Margin | 24.5% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings
Mar 27Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates
Apr 07There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings
Mar 30SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?
Mar 08SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years
Jan 25Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates
Dec 30Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?
Dec 29Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?
Dec 08A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)
Nov 17Revenue & Expenses BreakdownBeta
How SCI Pharmtech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,204 | 295 | 141 | 49 |
30 Sep 23 | 1,139 | 377 | 127 | 49 |
30 Jun 23 | 1,185 | 390 | 133 | 45 |
31 Mar 23 | 1,053 | 331 | 136 | 43 |
31 Dec 22 | 900 | 309 | 133 | 40 |
30 Sep 22 | 810 | 210 | 120 | 37 |
30 Jun 22 | 733 | 192 | 113 | 35 |
31 Mar 22 | 729 | 55 | 101 | 32 |
31 Dec 21 | 864 | 56 | 104 | 30 |
30 Sep 21 | 1,227 | -203 | 67 | 33 |
30 Jun 21 | 1,677 | -44 | 89 | 37 |
31 Mar 21 | 2,229 | 193 | 143 | 40 |
31 Dec 20 | 2,689 | 360 | 179 | 43 |
30 Sep 20 | 2,711 | 728 | 233 | 42 |
30 Jun 20 | 2,660 | 699 | 234 | 40 |
31 Mar 20 | 2,536 | 615 | 206 | 39 |
31 Dec 19 | 2,356 | 571 | 200 | 39 |
30 Sep 19 | 2,300 | 592 | 196 | 39 |
30 Jun 19 | 2,192 | 559 | 196 | 38 |
31 Mar 19 | 2,118 | 550 | 216 | 37 |
31 Dec 18 | 1,940 | 447 | 197 | 37 |
30 Sep 18 | 1,809 | 396 | 194 | 35 |
30 Jun 18 | 1,644 | 310 | 183 | 35 |
31 Mar 18 | 1,398 | 201 | 143 | 34 |
31 Dec 17 | 1,301 | 191 | 128 | 33 |
30 Sep 17 | 1,226 | 166 | 142 | 33 |
30 Jun 17 | 1,348 | 220 | 155 | 33 |
31 Mar 17 | 1,586 | 311 | 181 | 33 |
31 Dec 16 | 1,903 | 417 | 238 | 36 |
30 Sep 16 | 1,994 | 444 | 233 | 36 |
30 Jun 16 | 1,956 | 445 | 220 | 36 |
31 Mar 16 | 2,013 | 438 | 220 | 36 |
31 Dec 15 | 1,811 | 374 | 180 | 35 |
30 Sep 15 | 1,795 | 360 | 172 | 37 |
30 Jun 15 | 1,724 | 326 | 162 | 38 |
31 Mar 15 | 1,560 | 294 | 150 | 37 |
31 Dec 14 | 1,492 | 265 | 148 | 36 |
30 Sep 14 | 1,460 | 254 | 150 | 37 |
30 Jun 14 | 1,440 | 217 | 181 | 34 |
31 Mar 14 | 1,330 | 170 | 170 | 33 |
31 Dec 13 | 1,293 | 160 | 159 | 32 |
30 Sep 13 | 1,300 | 179 | 157 | 28 |
30 Jun 13 | 1,267 | 203 | 118 | 31 |
Quality Earnings: 4119 has a high level of non-cash earnings.
Growing Profit Margin: 4119's current net profit margins (24.5%) are lower than last year (34.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4119's earnings have declined by 20.9% per year over the past 5 years.
Accelerating Growth: 4119's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4119 had negative earnings growth (-4.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15%).
Return on Equity
High ROE: 4119's Return on Equity (5.8%) is considered low.